Live Breaking News & Updates on Toxicity comparison

Stay updated with breaking news from Toxicity comparison. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

Experts discuss the impact of elacestrant on patient well-being, including potential cardiovascular and gastrointestinal toxicities, quality of life, and patient feedback regarding access to treatment.

William-gradishar , Gregory-vidal , Rena-callahan , Mabel-mardones , Peer-exchange , European-society-for-medical-oncology-congress , Medical-oncology-congress , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances

Elacestrant: Treatment Considerations, Including Dosing and Compliance

Experts explore treatment considerations when treating patients with metastatic breast cancer with elacestrant, including dosing, patient selection, adherence, and treatment duration. Participants also discuss dose modifications, adherence concerns, and how they determine treatment failure.

William-gradishar , Mabel-mardones , Rena-callahan , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.

Rena-callahan , William-gradishar , Mabel-mardones , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.

William-gradishar , Rena-callahan , Mabel-mardones , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

Experts discuss how they determine whether a patient with metastatic breast cancer is a candidate for treatment with elacestrant based on FDA approved indication, NCCN guidelines, and the results of ESR1 mutation and resistance marker testing. Participants also discuss how they determine treatment failure or resistance.

Breast-cancer , Clinical-guidelines , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive , Her2-negative , Selective-estrogen-receptor-degrader

Managing Adverse Events in Patients Receiving Later Line Systemic Therapy for Metastatic TNBC

Dr. Noor Abuhadra discusses managing adverse events in patients receiving TRODELVY (sacituzumab govitecan), a later-line systemic therapy for metastatic triple-negative breast cancer. Shay Elkins, a patient, shares her experience with significant side effects including diarrhea, low white blood cell counts, and hair loss, while Dr. Abuhadra emphasizes the need for proactive management of these issues to maximize treatment time and maintain quality of life.

Metastatic-triple-negative-breast-cancer , Overcoming-challenges , Diagnosis-treatment , Adverse-events , Patients-receiving-later-line-systemic-therapy , Triple-negative-breast-cancer , Mtnbc , Trodelvy , Sacituzumab-govitecan , Side-effects , Blood-counts